FINHUB Insights

REGN · Q2 FY26 · Apr 1 – Jun 30, 2026

Regeneron Pharmaceuticals Q2 FY26: where the revenue came from and where it went

Regeneron Pharmaceuticals Q2 FY26: revenue $4.3B (+17% year over year). Net profit $1.3B. Largest cohort Collaboration $2.5B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2026
Reported
Jul 30, 2026 10-Q
Sankey diagram of Regeneron Pharmaceuticals's income statement for Q2 FY26: revenue of $4.29 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$4.29B +17% year over year
Gross profit$3.59B 84% margin
Operating profit$1.29B 30% margin
Net profit$1.30B 30% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
ItemValueShare of revenueYear over year
Revenue 4.29 100% +17%
Collaboration 2.46 57% +32%
Product 1.64 38% +1%
Service other 0.19 4% +5%
Cost of revenue−0.7016%
Gross profit3.5984% margin−2pp
R&D−1.6338%−1pp
SG&A−0.6615%−2pp
Operating profit1.2930% margin+1pp
Tax−0.23
Net profit1.3030%−8pp
Filing on EDGAR More quarters of REGN

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.